No Data
TRANSCENTA-B: SUPPLEMENTAL ANNOUNCEMENT
Express News | Transcenta Holding Limited FY Revenue RMB 11.3 Million
TRANSCENTA-B: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED DECEMBER 31, 2024;AND CHANGE IN USE OF PROCEEDS
TRANSCENTA-B (06628.HK) plans to hold a Board of Directors meeting on March 28 to approve annual performance.
Gelonghui March 14th丨TRANSCENTA-B (06628.HK) announced that the Board of Directors has scheduled a meeting on March 28, 2025, to consider and approve the annual performance of the group for the year ending December 31, 2024, and the proposed final dividend (if any), as well as to address Other matters.
TRANSCENTA-B: DATE OF BOARD MEETING
[Brokerage Focus] Softbank China gives a strong Buy rating to Chuangsheng Group (06628), indicating that its potential value is underestimated by the market.
Jinwu Financial News | Softbank China Research indicates that Chuangsheng Group (06628) has an experienced and comprehensive team, with Global clinical research and development capabilities in China and the USA. They employ a multi-regional development Global Strategy, utilizing proprietary antibody discovery platforms, integrated CMC capabilities, advanced translational science platforms, and HiCB manufacturing technology to advance innovations in drugs for various diseases, while also providing CDMO services to generate revenue. The company's core product Osemitamab (TST001) is a potentially best-in-class humanized antibody targeting Claudin18.2 (CLDN18.2).
